PregLem, the wholly owned subsidiary of Gedeon Richter, announces full results of PEARL I and II studies, published simultaneously in the New England Journal of Medicine (NEJM). The company has recently received positive EMA/CHMP opinion for Esmya® 5 mg (ulipristal acetate) in the pre-operative treatment of uterine fibroids (myomas) and is expecting a marketing authorization by the European Commission early this year.

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC® for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma. Under the terms of the agreement, EUSA will pay Alizé Pharma an upfront fee, regulatory milestone payments and royalties on future product sales.

Sequana Medical from Zürich, Switzerland has been nominated for one of the European medical-device industry’s most prestigious awards. Sequana Medical has been shortlisted for the Best Medical Device Start-Up of the Year prize in the 1st MEDTEC EMDT Innovation Awards. The Awards are the only European awards dedicated to recognising these achievements in the sector.

Santhera regains worldwide rights for fipamezole. Ipsen retains a call option for worldwide license to the program under certain conditions.